Print version
Search Pub Med
- J. Goulding1
- 2
- S. J. Mistry3
- 2
- S. J. Briddon1
- 2
- J. Woolard1
- 2
- B. Kellam3
- 2
- S. J. Hill1
- 2. 1Division of Physiology
- Pharmacology and Neuroscience
- School of Life Sciences
- University of Nottingham
- Nottingham
- United Kingdom
- 2Compare
- University of Nottingham
- Nottingham
- United Kingdom
- 3School of Pharmacy
- University of Nottingham
- Nottingham
- United Kingdom
036P Nottingham, UK 7th Focused Meeting on Cell Signalling |
BRET imaging of ligand interactions with the human β2 adrenoceptor using novel ICI 118,551 based fluorescent antagonists
Introduction: The β2 adrenoceptor (β2AR) is a G protein-coupled receptor implicated in the pathology of asthma and heart disease. Fluorescent antagonists allow both visualisation and study of real-time ligand-receptor interactions in living cells. However few highly selective β2AR fluorescent antagonists are available. Therefore, we have synthesised three new fluorescent analogues of the selective β2AR antagonist ICI-118,551 (1, β2AR pKD 9.3) with varying linkers. We show that these ligands retain β2AR/β1AR selectivity and can be used for single cell ligand binding using Bioluminescence Resonance Energy Transfer (BRET) imaging.
Methods: Three BODIPY630/650-X conjugates of the 3-((3-hydroxy-4-((7-methyl-2,3-dihydro-1H-inden-4-yl)oxy)butan-2-yl)amino core of ICI-118,551 were synthesised with either a 3-(2-(2-(2-aminoethoxy)ethoxy)ethyl- or dipeptidyl (Gly-Ala/β-Ala-β-Ala) linkers. Confocal imaging was performed with a Zeiss LSM880 microscope using HEK293 cells stably expressing an N-terminal SNAP-tagged β2AR (SNAP_β2AR) labelled with 0.5µM SNAPSurface488. Whole cell saturation NanoBRET ligand binding assays were performed on HEK293 cells stably expressing N-terminal nanoluciferase- (Nluc) tagged human β2AR or β1AR as previously reported (2). BRET imaging was performed on Nluc_β2AR cells on an Olympus LV200 bioluminescence microscope using furimazine (4μM) and fluorescent antagonist (100nM). Emission was collected at 438/24nm bandpass filter (20s) and 647nm Long Pass (4min) and image analysis performed using Fiji plugin Time Series Analyzer V3.
Results: Clear saturable specific binding was detected at the β2AR using NanoBRET with all three fluorescent ICI,118551 analogues (Table 1). The polyether linked ICI118,551-BODIPY630/650-X conjugate (PEG3) demonstrated the highest affinity and selectivity for the β2AR (Table 1). Confocal imaging of all three antagonists displayed membrane binding, co-localising with that of the SNAP_ β2AR. Displaceable binding (10μM propranolol) was observed for the Gly-Ala-ICI118,551-BY650/650X conjugate by confocal imaging and by BRET imaging for the β-Ala-β-Ala-ICI118,551-BY650/650X and PEG3-ICI118,551-BY650/650X conjugates.
Linker | β2AR pKD | β1AR pKD |
PEG3 | 7.74 ± 0.05 (6) | <5 (5) |
Gly-Ala | 7.06 ± 0.10 (5) | <5 (4) |
β-Ala-β-Ala | 7.36 ± 0.15 (5) | 6.32 ± 0.25 (5) |
Table 1. Affinity of ICI118,551 derivatives at the human β1 and β2AR in HEK293 cells using NanoBRET saturation binding. Data represent mean ± S.E.M of n repeat experiments performed in duplicate. 10μM propranolol was used to define non-specific binding.
Conclusion: We have developed novel selective β2AR fluorescent antagonists that can be used for confocal and BRET imaging. We thank the MRC for financial support.
References:
1 Baker (2005). Br J Pharmacol 144(3): 317-22
2 Stoddart et al. (2015). Nat Methods 12(7): 661-663.